Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;94(8):3515-3516.
doi: 10.1002/jmv.27802. Epub 2022 Apr 28.

Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID-19 infections?

Massimiliano Lanzafame  1 , Enrico Gibbin  2 , Emanuela Lattuada  2 , Sandro Vento  3
Affiliations

Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID-19 infections?

Massimiliano Lanzafame et al. J Med Virol. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19. N Engl J Med. 2021;384:238‐251. 10.1056/NEJMoa2035002 - DOI - PMC - PubMed
    1. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in mild or moderate Covid‐19. N Engl J Med. 2021;385:1382‐1392. 10.1056/NEJMoa2102685 - DOI - PMC - PubMed
    1. Bierle DM, Ganesh R, Tulledge‐Scheitel S, et al. Monoclonal antibody treatment of breakthrough COVID‐19 in fully vaccinated individuals with high‐risk comorbidities. J Infect Dis. 2022;225:598‐602. https://academic.oup.com/jid/article/225/4/598/6429422 - PMC - PubMed
    1. Yetmar ZA, Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID‐19 after SARS‐CoV‐2 vaccination in solid organ transplant recipients: an analysis of symptomatic cases and monoclonal antibody therapy. Transpl Infect Dis. 2022;24:e13779. 10.1111/tid.13779 - DOI - PubMed
    1. Ganesh R, Philpot LM, Bierle DM, et al. Real‐world clinical outcomes of Bamlanivimab and Casirivimab‐Imdevimab among high‐risk patients with mild to moderate Coronavirus Disease 2019. J Infect Dis. 2021;224:1278‐1286. https://academic.oup.com/jid/article/224/8/1278/6323936 - PMC - PubMed

Supplementary concepts